Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence?

Cognitive Effects of Oxybutynin Chloride Topical Gel in Older Healthy Subjects

(2013) Gary G. Kay et al.   CLINICAL DRUG INVESTIGATION

Randomised, Multicentre, Placebo-controlled, Double-blind Crossover Study Investigating the Effect of Solifenacin and Oxybutynin in Elderly People with Mild Cognitive Impairment: The SENIOR Study

(2013) Adrian Wagg et al.   EUROPEAN UROLOGY

Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience

(2012) Adrian Wagg et al.   BJU INTERNATIONAL

An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study

(2012) Lorne E. Aaron et al.   CURRENT MEDICAL RESEARCH AND OPINION

Antimuscarinic Treatment in Overactive Bladder

(2012) Adrian S. Wagg   DRUGS & AGING

Efficacy and Adverse Events of Antimuscarinics for Treating Overactive Bladder: Network Meta-analyses

(2012) Nora Buser et al.   EUROPEAN UROLOGY

Oxybutynin: past, present, and future

(2012) Kelly Jirschele et al.   INTERNATIONAL UROGYNECOLOGY JOURNAL

American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults

(2012)   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Evaluation of Cognitive Function in Healthy Older Subjects Treated with Fesoterodine

(2012) Gary G. Kay et al.   POSTGRADUATE MEDICINE

Improving recruitment of older people to research through good practice

(2011) Marion E. T. McMurdo et al.   AGE AND AGEING

Cost-effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry

(2011) Fredrik O.L. Nilsson et al.   BJU INTERNATIONAL

A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder

(2011) Ernesto Callegari et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study

(2011) D.-S. Yoo et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Systematic Review and Meta-Analysis: Do Clinical Trials Testing Antimuscarinic Agents for Overactive Bladder Adequately Measure Central Nervous System Adverse Events?

(2011) Amélie Paquette et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Effect of oxybutynin and imidafenacin on central muscarinic receptor occupancy and cognitive function: A monkey PET study with [11C](+)3-MPB

(2011) Shigeyuki Yamamoto et al.   NEUROIMAGE

Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach

(2011) Thomas M. Kessler et al.   PLoS One

The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service

(2010) Linda Cardozo et al.   BJU INTERNATIONAL

Tolerability of solifenacin and oxybutynin immediate release in older (>65 years) and younger (≤65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study

(2010) S. Herschorn et al.   CURRENT MEDICAL RESEARCH AND OPINION

Overactive Bladder Drugs and Constipation: A Meta-Analysis of Randomized, Placebo-Controlled Trials

(2010) Patrick D. Meek et al.   DIGESTIVE DISEASES AND SCIENCES

Dynamic Progression of Overactive Bladder and Urinary Incontinence Symptoms: A Systematic Review

(2010) Debra E. Irwin et al.   EUROPEAN UROLOGY

Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder

(2010) D. Staskin et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Efficacy of Oral Extended-Release Oxybutynin in Cognitively Impaired Older Nursing Home Residents With Urge Urinary Incontinence: A Randomized Placebo-Controlled Trial

(2010) Thomas E. Lackner et al.   Journal of the American Medical Directors Association

Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography

(2010) Akira Yoshida et al.   LIFE SCIENCES

Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder

(2010) S. Herschorn et al.   JOURNAL OF MEDICAL ECONOMICS

Constipation in old age

(2009) Paul Gallagher et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Blood-brain barrier alterations in ageing and dementia

(2009) Bogdan O. Popescu et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria

(2008) P. Gallagher et al.   AGE AND AGEING

Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin

(2008) G. G. Kay et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Randomized, Placebo-Controlled Trial of the Cognitive Effect, Safety, and Tolerability of Oral Extended-Release Oxybutynin in Cognitively Impaired Nursing Home Residents with Urge Urinary Incontinence

(2008) Thomas E. Lackner et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Dual Use of Bladder Anticholinergics and Cholinesterase Inhibitors: Long-Term Functional and Cognitive Outcomes

(2008) Kaycee M. Sink et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY